ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,111Medicare Part D Prescriptions Filled, Including Refills

Rank: 67 out of 1155

$395K Total Retail Price of All Prescriptions

Rank: 114 out of 1155

462 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
34% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 462 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

16% of this provider’s 462 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

2% of this provider’s 6,922 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$43 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
SIMVASTATIN 359 311 1 3
LISINOPRIL 357 292 2 1
AMLODIPINE BESYLATE 322 265 3 6
LEVOTHYROXINE SODIUM 292 246 4 2
HYDROCODONE-ACETAMINOPHEN 275 228 S3 5 4
OMEPRAZOLE 261 153 6 5
HYDROCHLOROTHIAZIDE 254 241 7 9
METFORMIN HCL 254 208 7 7
ATORVASTATIN CALCIUM 238 204 9 12
CITALOPRAM HBR 197 148 10 19
PRAVASTATIN SODIUM 188 161 11 20
LISINOPRIL-HYDROCHLOROTHIAZIDE 179 148 12 26
METOPROLOL TARTRATE 170 153 13 14
LOSARTAN POTASSIUM 162 133 14 18
FUROSEMIDE 155 107 15 8
ATENOLOL 143 125 16 10
METOPROLOL SUCCINATE 126 119 17 17
ALENDRONATE SODIUM 119 99 18 25
ZOLPIDEM TARTRATE 115 72 19 21
GABAPENTIN 109 69 20 15
GLIMEPIRIDE 105 98 21 43
TAMSULOSIN HCL 104 96 22 27
WARFARIN SODIUM 101 83 23 11
TRAZODONE HCL 99 53 24 22
POTASSIUM CHLORIDE 96 66 25 16
CRESTOR 88 80 26 34
ESTRADIOL 87 45 R 27 60
LOVASTATIN 85 65 28 13
CARVEDILOL 79 72 29 28
TRIAMTERENE-HCTZ 77 51 30 51
SERTRALINE HCL 73 44 31 24
DICLOFENAC SODIUM 70 66 32 93
GEMFIBROZIL 62 43 33 78
ALLOPURINOL 60 54 34 29
PAROXETINE HCL 59 40 35 48
CYCLOBENZAPRINE HCL 56 26 R 36 38
OXYBUTYNIN CHLORIDE ER 55 23 37 130
METFORMIN HCL ER 55 51 37 53
AMLODIPINE BESYLATE-BENAZEPRIL 52 27 39 119
NAMENDA 52 52 39 67
LIPITOR 51 38 41 138
FELODIPINE ER 51 51 41 128
OXYCODONE HCL 50 11 S2 43 23
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 30, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.